Catalyst Pharmaceuticals Inc(NASDAQ:CPRX) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Earnings per share were $-0.06. Analysts had estimated an EPS of $-0.08.
Catalyst Pharmaceuticals Inc (CPRX) made into the market gainers list on Wednesdays trading session with the shares advancing 6.30% or 0.0478 points. Due to strong positive momentum, the stock ended at $0.807, which is also near the day’s high of $0.8701. The stock began the session at $0.769 and the volume stood at 16,63,110 shares. The 52-week high of the shares is $4.5244 and the 52 week low is $0.51. The company has a current market capitalization of $67 M and it has 8,28,70,649 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jul 12, 2016, Charles B O’keeffe (director) purchased 20,000 shares at $0.81 per share price.Also, On Jun 14, 2016, Donald A Denkhaus (director) purchased 50,000 shares at $0.65 per share price.On Jun 14, 2016, Patrick J Mcenany (CEO) purchased 105,300 shares at $0.65 per share price, according to the Form-4 filing with the securities and exchange commission.
Catalyst Pharmaceuticals Inc. formerly Catalyst Pharmaceutical Partners Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse CPP-109 and CPP-115. Firdapse is used for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). CPP-115 is used for the treatment of addiction and epilepsy. CPP-109 is used to treat addiction. The Company is conducting a Phase III trial to determine the safety and efficacy of Firdapse in the treatment of LEMS. CPP-115 has been granted Orphan Drug Designation by the food and drug administration (FDA) for the treatment of infantile spasms and Orphan Medicinal Product Designation in the European Union for West syndrome (a form of infantile spasms).